4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Lowered to $27.00 at Leerink Partners

4D Molecular Therapeutics (NASDAQ:FDMT) had its target price cut by analysts at Leerink Partners from $31.00 to $27.00 in a report released on Monday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Leerink Partners’ price objective points to a potential upside of 462.50% from the stock’s current price.

A number of other research firms also recently commented on FDMT. Chardan Capital restated a “buy” rating and set a $39.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday, November 14th. Morgan Stanley cut their target price on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating for the company in a research report on Monday. Royal Bank of Canada cut their price objective on 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a report on Thursday, November 14th. Cantor Fitzgerald lowered shares of 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, September 23rd. Finally, HC Wainwright reiterated a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Monday. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $38.56.

4D Molecular Therapeutics Stock Down 13.0 %

4D Molecular Therapeutics stock traded down $0.72 during mid-day trading on Monday, hitting $4.80. 528,240 shares of the company’s stock traded hands, compared to its average volume of 682,908. 4D Molecular Therapeutics has a one year low of $4.68 and a one year high of $36.25. The company has a market cap of $221.89 million, a PE ratio of -1.68 and a beta of 2.81. The firm has a 50 day moving average price of $7.00 and a 200 day moving average price of $11.99.

Institutional Trading of 4D Molecular Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. nVerses Capital LLC acquired a new stake in shares of 4D Molecular Therapeutics during the third quarter worth $40,000. Values First Advisors Inc. bought a new stake in shares of 4D Molecular Therapeutics during the third quarter worth $57,000. China Universal Asset Management Co. Ltd. raised its stake in shares of 4D Molecular Therapeutics by 64.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock valued at $108,000 after purchasing an additional 3,922 shares during the period. Proficio Capital Partners LLC acquired a new position in shares of 4D Molecular Therapeutics during the third quarter worth about $108,000. Finally, Quest Partners LLC grew its holdings in shares of 4D Molecular Therapeutics by 17,409.1% during the second quarter. Quest Partners LLC now owns 5,778 shares of the company’s stock worth $121,000 after buying an additional 5,745 shares in the last quarter. 99.27% of the stock is currently owned by institutional investors and hedge funds.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.